Immunovant, Inc.

Equities

IMVT

US45258J1025

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 22/06/2024 am IST			5-day change	1st Jan Change
27.32 ^USD	+0.11%		+5.08%	-35.15%

03/06	Oppenheimer Adjusts Immunovant Price Target to $46 From $50, Maintains Outperform Rating	MT
30/05	Sector Update: Health Care Stocks Mixed Pre-Bell Thursday	MT

Immunovant, Inc. Reports Earnings Results for the Full Year Ended March 31, 2023

May 22, 2023 at 04:40 pm IST

Immunovant, Inc. reported earnings results for the full year ended March 31, 2023. For the full year, the company reported net loss was USD 210.96 million compared to USD 156.73 million a year ago. Basic loss per share from continuing operations was USD 1.71 compared to USD 1.43 a year ago.

Latest news about Immunovant, Inc.

Oppenheimer Adjusts Immunovant Price Target to $46 From $50, Maintains Outperform Rating	03/06	MT
Sector Update: Health Care Stocks Mixed Pre-Bell Thursday	30/05	MT
Immunovant Q4 Loss Widens -- Shares Fall After-Hours	30/05	MT
Immunovant, Inc. Reports Earnings Results for the Full Year Ended March 31, 2024	30/05	CI
Immunovant, Inc. Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	30/05	CI
Immunovant Insider Sold Shares Worth $479,233, According to a Recent SEC Filing	25/05	MT
Immunovant Insider Sold Shares Worth $990,269, According to a Recent SEC Filing	20/04	MT
Immunovant Insider Sold Shares Worth $293,923, According to a Recent SEC Filing	20/04	MT
Oppenheimer Initiates Coverage on Immunovant With Outperform Rating, $50 Price Target	28/03	MT
Goldman Sachs Starts Coverage on Immunovant With Buy Rating, $50 Price Target	13/03	MT
Immunovant Insider Sold Shares Worth $486,362, According to a Recent SEC Filing	24/02	MT
JPMorgan Starts Coverage on Immunovant With Overweight Rating, $51 Price Target	20/02	MT
Wolfe Research Starts Immunovant With Outperform Rating, $55 Price Target	15/02	MT
Immunovant Posts Narrower Fiscal Q3 Loss	12/02	MT
Immunovant, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	12/02	CI
North American Morning Briefing : Stock Futures -2-	09/02	DJ
North American Morning Briefing : Jobs Report Tops -2-	02/02	DJ
Immunovant Insider Sold Shares Worth $383,012, According to a Recent SEC Filing	30/01	MT
Transcript : Immunovant, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 07:30 AM	09/01
Sector Update: Health Care Stocks Edge Higher Premarket Thursday	21/12	MT
HC Wainwright Adjusts Price Target on Immunovant to $51 From $47, Keeps Buy Rating	21/12	MT
Immunovant Gets Positive Data From Graves' Disease Treatment Trial	21/12	DJ
Immunovant's Batoclimab for Graves' Disease Produces Meaningful Response Rates in Study; Shares Jump After Hours	21/12	MT
Immunovant, Inc. Announces Results from the Initial Cohort of Patients in an Ongoing 24-Week Phase 2 Clinical Trial of Batoclimab in Patients with Graves' Disease Meaningfully Exceeded 50% Response Rates	21/12	CI
Top Premarket Decliners	20/12	MT

Chart Immunovant, Inc.

Duration

Period

More charts

Company Profile

Immunovant, Inc. is a clinical-stage immunology company. The Company is focused on developing treatments for patients with autoimmune diseases. Its product pipeline includes batoclimab and IMVT-1402, both of which are novel, fully human monoclonal antibodies that target the neonatal fragment crystallizable receptor (FcRn). Batoclimab is a subcutaneous injection with dosing. Batoclimab is observed to reduce immunoglobulin G (IgG) antibodies that cause inflammation and disease. Its product candidate, batoclimab, is dosed in small volumes and with a 27-gauge needle. It is developing batoclimab for myasthenia gravis (MG), thyroid eye disease (TED), chronic inflammatory demyelinating polyneuropathy (CIDP) and Gravesâ disease (GD). Its lead product candidate IMVT-1402 has also been observed to reduce IgG antibody levels in a Phase I clinical trial conducted in healthy adults. IMVT-1402 is a fully human monoclonal antibody that inhibits FcRn.

Sector

Biotechnology & Medical Research

Calendar

07/08/2024 - Q1 2025 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

27.32 USD

Average target price

49.14 USD

Spread / Average Target

+79.88%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IMMUNOVANT, INC.	-35.15%	399.02Cr
MODERNA, INC.	+34.14%	5.11TCr
IQVIA HOLDINGS INC.	-6.54%	3.94TCr
LONZA GROUP AG	+34.92%	3.85TCr
ICON PUBLIC LIMITED COMPANY	+12.62%	2.64TCr
CELLTRION, INC.	-12.11%	2.62TCr
ALNYLAM PHARMACEUTICALS, INC.	-13.43%	2.1TCr
UNITED THERAPEUTICS CORPORATION	+43.73%	1.4TCr
MEDPACE HOLDINGS, INC.	+31.81%	1.25TCr
BIO-TECHNE CORPORATION	-4.54%	1.16TCr

Other Biotechnology & Medical Research